Takeda Highlights Rare Neurological Disorder Programs In Wave 1
Company Already Has Pivoted Away From Larger Psychiatric Indications
Executive Summary
Seeing significant unmet medical needs and insufficiently met needs in narcolepsy and rare types of epilepsy, Takeda has shifted its neuroscience focus.
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
In this week's podcast version of Five Must-Know Things, hear about whether safety concerns may affect JAK inhibitors, Takeda’s strategic R&D plans, Cigna’s psoriasis insurance program, Phase III readouts to look for, and an overview of the global pharma R&D pipeline.
Takeda Takes Back Dravet, Lennox-Gastaut Candidate From Ovid
Revising the two companies’ 2017 epilepsy collaboration, Takeda will take over Phase III development and commercialization of soticlestat. Ovid gets $196m up front, and it can shift focus.
Takeda’s Andy Plump Tells The Japanese Pharma’s New Story
As Takeda pays down debt associated with the acquisition of Shire and advances R&D programs toward global filings, the company is selling its growth plan to investors – but are they buying?